TABLE 3.
Some case reports and clinical characteristics of patients with ifosfamide‐induced nephrotoxicity
| Study | Type of cancer | Age/sex | cumulative dose of ifosfamide (g/m2) | Out come | Risk factors for AKI | Ref |
|---|---|---|---|---|---|---|
| Sohail et al. (2021) | Synovial cell sarcoma | 36/Female | 7.5 | Ifosfamide‐induced nephrogenic diabetes insipidus | Unknown risk factors | [20] |
| Aisyi et al. (2020) | Wilms tumor | 3/Male | Not reported | Fanconi syndrome | Wilms tumor and Multiple Ifosfamide regime | [21] |
| Sokolova et al. (2017) | Non‐seminomatous germ cell tumor | 21/Male | 4 | Delayed rhabdomyolysis after high‐dose chemotherapy | Paclitaxel, ifosfamide, carboplatin, and etoposide regimen | [22] |
| Matsuura et al. (2014) | Osteosarcoma | 15/Male | 69.7 | Acute interstitial nephritis (Karyomegalic) | High cumulative dose and the combination of cisplatin | [23] |
| Kamran et al. (2014) | Rhabdomyosarcoma | 26/Female | 23.4 | Fanconi syndrome and nephrogenic diabetes insipidus | Unknown risk factors | [24] |
| Lee et al. (2014) | Synovial sarcoma | 25/Female | 39 | Fanconi syndrome | Possible effect of high dose | [15] |
| Kim et al. (2008) | Ovarian cancer | 32/Female | 10 | Proximal Tubule Injury | Combination of cisplatin and ifosfamide | [25] |
| Hill et al. (2000) | Breast cancer | Three women with age 40–50 | 20–30 | Tubulo‐interstitial nephritis | High‐dose chemotherapy | [26] |